Lipocine Gets FDA Nod For Mid-Stage Epilepsy Study

The U.S. Food and Drug Administration (FDA) has accepted the Lipocine’s (NASDAQ: LPCN ) Investigational New Drug Application (IND) for its candidate, LPCN 2101 in adults with epilepsy.  The Phase 2 clinical study is designed to evaluate the safety, tolerability, and efficacy of oral LPCN ... Full story available on Benzinga.com